Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library
Suprefort (pancreas peptide complex): what the evidence says
At a glance
What it is: an oral capsule product sold as one of the Khavinson "Cytomax" natural peptide complexes, said to be extracted from young animal pancreas (product code A-1). UNVERIFIED the product code, the source tissue and the manufacturing method; these come from Nova's spec and seller descriptions, not from a primary source we could open.
What the evidence says: a PubMed search on Oct 27, 2026 found no study naming Suprefort. The closest records concern the synthetic tetrapeptide pancragen, such as a pancreatic-cell culture study; that is a different product. R1
Biggest risks: unknown. Animal-tissue extracts carry a theoretical risk of allergy and contamination, and the contents of a given capsule are not standardized. UNVERIFIED no safety data were found.
Rating
| Human Human evidence | None found |
| Animal Animal / lab evidence | Only related Khavinson-group reviews R1 |
| Regulatory | Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page R2, R3, R4 · not named by WADA R5 |
| Established human dose | No |
Evidence verdict: Any health use: Unknown (no peer-reviewed human trial found naming this product)
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence: there is nothing specific to this product to grade. Claims for it rest on the wider Khavinson peptide-bioregulator literature, which comes mostly from one research group in St. Petersburg and has not been independently replicated in Western randomized trials.
What is it?
A dietary-supplement-style capsule of a tissue-derived peptide mixture, marketed alongside the synthetic tetrapeptide pancragen. Related pages: pancragen.
Does it work?
- Unknown No peer-reviewed human or animal study naming this product was found in PubMed.
- Animal Related context only: The closest records concern the synthetic tetrapeptide pancragen, such as a pancreatic-cell culture study; that is a different product. R1 R1
Is it safe?
- Unknown No safety data found.
Gray-market vials: extra risks
A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.
Is it legal?
- US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 27, 2026).
- Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. R2, R3, R4
- Sport: not named on WADA's 2026 Prohibited List. R5
Study details
Study details
These are amounts researchers used, not recommendations.
| Study | People / model | Route | Amount used | Follow-up | Reported | Citation |
|---|---|---|---|---|---|---|
| No study found | — | — | — | — | No PubMed record names this product (searched Oct 27, 2026) | — |
Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)
- R1 Khavinson VKh, et al. Bull Exp Biol Med. 2013. PMID 23486591
- R2 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
- R3 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
- R4 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- R5 WADA. The 2026 Prohibited List, full list checked; compound not named. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use Suprefort (pancreas peptide complex). This compound is not FDA-approved. Any product sold under this name in the US is unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).